Home
/ SUSMED
/ Competitors

SUSMED Competitors and Similar CompaniesClear all

SUSMED's competitors and similar companies include CEL-SCI, Kinnov Therapeutics, Upstream Bio and Albert Labs.

	SUSMED SUSMED is a digital therapeutics (DTx) development business.	CEL-SCI CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.	Kinnov Therapeutics Kinnov Therapeutics is a company dedicated to the research and development of therapies against addiction.	Upstream Bio Upstream Bio is a clinical-stage biotechnology company that develops treatments for inflammatory diseases.	Albert Labs Albert Labs is a clinical research and drug development company.
Founding Date	Founding Date 2015	Founding Date 1983	Founding Date N/A	Founding Date 2021	Founding Date 2009
Type	Type Public	Type Public	Type Private	Type Public	Type Public
Tags	Tags Healthcare clinical research drug development therapy	Tags Healthcare biotech clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy
Locations	Locations Chuo City, JP HQ	Locations Vienna, US HQ	Locations Orléans, FR HQ	Locations Waltham, US HQ	Locations Burnaby, CA HQ Porto, PT Manchester, GB
Employees	Employees 39	Employees N/A	Employees N/A	Employees 38	Employees N/A
Valuation ($)	Valuation ($) 64.9 m	Valuation ($) 58.7 m	Valuation ($) N/A	Valuation ($) 1.3 b	Valuation ($) 401.7 k
Financial
Revenue (est.)	Revenue (est.) ¥463m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $2.9m (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods ¥4.3m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods $23m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit ¥458.7m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit ($20.2m) (FY, 2025)	Gross profit N/A
Net income	Net income (¥298.4m) (FY, 2025)	Net income ($25.4m) (FY, 2025)	Net income N/A	Net income ($143.4m) (FY, 2025)	Net income ($7.1m) (FY, 2022)